Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1360
Snehal M. Shinde, Priti U. More, S. Borkar, Vishal D. Yadav, Swapnil D. Zambare, Shrikrushn B. Sontakke
Medical professionals have long had trouble delivering medications to the correct location in the body and controlling their release to prevent overdose. Nano-sponges are novel and complicated molecules, which have the ability to alleviate these challenges. Utilizing nano-sponges allows for precise drug delivery to the desired location. Nano-sponge technology gets better patient compliance by delivering drugs to strategic locations while also extending dosing intervals. Various drug delivery techniques, such as parenteral, transdermal, oral, and immunosuppressive drugs, involve Nano-sponges. In today's world, nanosponges are used in gastro-retentive drug delivery systems.
{"title":"New Trends in Emerging Novel Nanosponges Drug Delivery","authors":"Snehal M. Shinde, Priti U. More, S. Borkar, Vishal D. Yadav, Swapnil D. Zambare, Shrikrushn B. Sontakke","doi":"10.22270/ajprd.v12i2.1360","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1360","url":null,"abstract":"Medical professionals have long had trouble delivering medications to the correct location in the body and controlling their release to prevent overdose. Nano-sponges are novel and complicated molecules, which have the ability to alleviate these challenges. Utilizing nano-sponges allows for precise drug delivery to the desired location. Nano-sponge technology gets better patient compliance by delivering drugs to strategic locations while also extending dosing intervals. Various drug delivery techniques, such as parenteral, transdermal, oral, and immunosuppressive drugs, involve Nano-sponges. In today's world, nanosponges are used in gastro-retentive drug delivery systems.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140703912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1339
Pallav Dave
Pain is a symptom that is reported in cancer patients with the prevalence varying from 33% to 64%. Addressing pain remains a critical aspect of cancer treatment with research showing that pain management in this population remains inadequate. Addressing pain is instrumental because of the impact it has on a patient’s life. It affects clinical outcomes, contributes to poor quality of life, and leads to psychological distress. Barriers remain the key challenge that contributes to inadequate management. Addressing these barriers can lead to better outcomes. Carrying out a comprehensive patient assessment and screening is recommended before beginning pain management. Pain is multidimensional in nature and for many patients, different factors may be contributing to pain. Conducting a comprehensive assessment helps to identify these factors. Comprehensive assessment also helps to capture important information that can contribute to better pain management. After conducting an assessment, pain management should begin. Cancer pain can be managed using pharmacological and non-pharmacological interventions. The interventions should aim to improve patient comfort and function. The interventions should also provide more benefits than adverse effects. One of the mainstay interventions in managing cancer pain is opioids. Opioids should be given in accordance with recommendations from different guidelines to ensure they are effective.
{"title":"Recommendations for Pain Management in Cancer Patients","authors":"Pallav Dave","doi":"10.22270/ajprd.v12i2.1339","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1339","url":null,"abstract":"Pain is a symptom that is reported in cancer patients with the prevalence varying from 33% to 64%. Addressing pain remains a critical aspect of cancer treatment with research showing that pain management in this population remains inadequate. Addressing pain is instrumental because of the impact it has on a patient’s life. It affects clinical outcomes, contributes to poor quality of life, and leads to psychological distress. Barriers remain the key challenge that contributes to inadequate management. Addressing these barriers can lead to better outcomes. Carrying out a comprehensive patient assessment and screening is recommended before beginning pain management. Pain is multidimensional in nature and for many patients, different factors may be contributing to pain. Conducting a comprehensive assessment helps to identify these factors. Comprehensive assessment also helps to capture important information that can contribute to better pain management. After conducting an assessment, pain management should begin. Cancer pain can be managed using pharmacological and non-pharmacological interventions. The interventions should aim to improve patient comfort and function. The interventions should also provide more benefits than adverse effects. One of the mainstay interventions in managing cancer pain is opioids. Opioids should be given in accordance with recommendations from different guidelines to ensure they are effective.\u0000 \u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140703788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1376
D. Kanani, Dr. Rajesh Kumar Sharma, Dr. Vipul Sangani, D. Varsadiya
The sign and symptoms as well as morphology of stone found in Mutrashmari are similar to that of Urolithiasis.In Shushruta Samhita Ashmari included in Ashtamahagada due to its notorious nature and reluctant to cure.Urolithiasis is third most common affliction of the urinary tract,exceeded only by UTI and BPH.The classical symptoms of Ashmariis pain with obstruction of urine.It is one of the common disease conditions worldwide and it is found that Ashmarirecurs in spite of Surgical and Palliative intervention which shows the importance of diet and lifestyle in the manifestation of Mutrashmari. Hence it is very important to know all the aspect of this urinary problem so,that it can be nipped in the bud.
{"title":"A Classical Ayurveda and Modern Review of Mutrashmariw S.R.Urolithiasis","authors":"D. Kanani, Dr. Rajesh Kumar Sharma, Dr. Vipul Sangani, D. Varsadiya","doi":"10.22270/ajprd.v12i2.1376","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1376","url":null,"abstract":"The sign and symptoms as well as morphology of stone found in Mutrashmari are similar to that of Urolithiasis.In Shushruta Samhita Ashmari included in Ashtamahagada due to its notorious nature and reluctant to cure.Urolithiasis is third most common affliction of the urinary tract,exceeded only by UTI and BPH.The classical symptoms of Ashmariis pain with obstruction of urine.It is one of the common disease conditions worldwide and it is found that Ashmarirecurs in spite of Surgical and Palliative intervention which shows the importance of diet and lifestyle in the manifestation of Mutrashmari. Hence it is very important to know all the aspect of this urinary problem so,that it can be nipped in the bud.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The spectrophotometry provides versatile techniques for analyse drug in multi component pharmaceutical formulation in presence of various interferences. Simple, accurate, sensitive, precise and rapid UV-Spectrophotometric methods have been developed for the estimation of fenofibrate in bulk and tablet dosage form formulation. To determine the absorption maximum, the drug fenofibrate were scanned in wavelength range of 200-400nm in spectra measurement mode using the double beam UV-Spectrophotometer, 290 nm was selected as a sampling wavelength in DMF as solvent. Beer’s limit was obeyed in the range of 2-10 µg/ml for fenofibrate. The correlation coefficient found to be satisfactory. Validation parameters such as its accuracy, linearity, precision, limit of detection (LOD), and limit of quantitation (LOQ) was studied for proposed method according to the ICH guidelines. Results of all parameters were found to be satisfactory. The proposed method can be used effectively for routine analysis and estimation of fenofibrate in bulk and dosage form. The result demonstrated that the proposed method is accurate, precise and reproducible.
{"title":"Development and Validation of Fenofibrate in Bulk and Tablets using UV-Spectroscopy: An Anti-Hypercholesterolemic Agent","authors":"Narender Boggula, Bhadru Banothu, Satya Sireesha Devu, Rama Rao Tadikonda, Kiran Rapolu","doi":"10.22270/ajprd.v12i2.1373","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1373","url":null,"abstract":"The spectrophotometry provides versatile techniques for analyse drug in multi component pharmaceutical formulation in presence of various interferences. Simple, accurate, sensitive, precise and rapid UV-Spectrophotometric methods have been developed for the estimation of fenofibrate in bulk and tablet dosage form formulation. To determine the absorption maximum, the drug fenofibrate were scanned in wavelength range of 200-400nm in spectra measurement mode using the double beam UV-Spectrophotometer, 290 nm was selected as a sampling wavelength in DMF as solvent. Beer’s limit was obeyed in the range of 2-10 µg/ml for fenofibrate. The correlation coefficient found to be satisfactory. Validation parameters such as its accuracy, linearity, precision, limit of detection (LOD), and limit of quantitation (LOQ) was studied for proposed method according to the ICH guidelines. Results of all parameters were found to be satisfactory. The proposed method can be used effectively for routine analysis and estimation of fenofibrate in bulk and dosage form. The result demonstrated that the proposed method is accurate, precise and reproducible.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140699826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1362
Adarsh Dubey, Abhishek Yadav
Artificial Intelligence (AI) is the future of pharmaceutical industries. We make our tasks easier with help of Artificial Intelligence in future. With help of Artificial Intelligence we can also increase in production in pharmaceutical industry, can be save of dangerous and risky works in the production or manufacturing. Artificial Intelligence can drugs designing in future and discover new drugs and determine the chemical structure of drugs. Artificial Intelligence is very important role play in clinical research. For the pharmacological action drugs are works with the target protein. Than this target proteins are show the pharmacological action and Artificial Intelligence is help in determination of target protein and Artificial Intelligence can easier the drug discovery related work. Artificial Intelligence will used in the marketing such as the patient or customer related information or data collection and deposition. Creation of essential and specialized advertisement for increase product Sell. Different type application will in pharmaceutical industry of Artificial intelligence. And AI will change the pharmaceutical industry or drug associated work and that is come new revolution in pharmacy. Many types AI robots are invented in various pharmacy fields for the help of human being in manufacturing or production in pharmaceutical industry. Artificial Intelligence will advantages and disadvantage for the human beings. This review aims that drug delivery nanosystems design, characterization, and production stand to benefit greatly from artificial intelligence (AI). Furthermore, the ability to perform reverse engineering and ongoing system optimisation is becoming possible with the help of big data.
{"title":"New Era’s of Artificial Intelligence in Pharmaceutical Industries","authors":"Adarsh Dubey, Abhishek Yadav","doi":"10.22270/ajprd.v12i2.1362","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1362","url":null,"abstract":"Artificial Intelligence (AI) is the future of pharmaceutical industries. We make our tasks easier with help of Artificial Intelligence in future. With help of Artificial Intelligence we can also increase in production in pharmaceutical industry, can be save of dangerous and risky works in the production or manufacturing. Artificial Intelligence can drugs designing in future and discover new drugs and determine the chemical structure of drugs. Artificial Intelligence is very important role play in clinical research. For the pharmacological action drugs are works with the target protein. Than this target proteins are show the pharmacological action and Artificial Intelligence is help in determination of target protein and Artificial Intelligence can easier the drug discovery related work. Artificial Intelligence will used in the marketing such as the patient or customer related information or data collection and deposition. Creation of essential and specialized advertisement for increase product Sell. Different type application will in pharmaceutical industry of Artificial intelligence. And AI will change the pharmaceutical industry or drug associated work and that is come new revolution in pharmacy. Many types AI robots are invented in various pharmacy fields for the help of human being in manufacturing or production in pharmaceutical industry. Artificial Intelligence will advantages and disadvantage for the human beings. This review aims that drug delivery nanosystems design, characterization, and production stand to benefit greatly from artificial intelligence (AI). Furthermore, the ability to perform reverse engineering and ongoing system optimisation is becoming possible with the help of big data.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1371
Cheolin Park, Youngdu Baek
Diabetes is a type of metabolic disease such as insufficient insulin secretion or poor functioning. It is characterized by high blood sugar, which increases blood glucose concentration, causes various symptoms and signs due to high blood sugar, and excrete glucose from urine.Diabetes mellitus is divided into types 1 and 2, and type 1 diabetes was previously called 'juvenile diabetes', and it is a disease caused by the inability to produce any insulin. Type 2 diabetes, which is relatively deficient in insulin, is characterized by insulin resistance.Insulin treatment is required for type 1 diabetes, but type 2 diabetes is based on lifestyle correction and may require additional drug administration. In addition, many patients or people concerned about diabetes use dietary supplements to control their blood sugar, but because of the side effects of prescription drugs and the lack of definitive clinical trials of dietary supplements, it is important to choose wisely between prescription drugs and dietary supplements with the advice of a physician or expert to treat or prevent diabetes.
{"title":"Between Medicines and Nutraceuticals in the Control of Diabetes Mellitus","authors":"Cheolin Park, Youngdu Baek","doi":"10.22270/ajprd.v12i2.1371","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1371","url":null,"abstract":"Diabetes is a type of metabolic disease such as insufficient insulin secretion or poor functioning. It is characterized by high blood sugar, which increases blood glucose concentration, causes various symptoms and signs due to high blood sugar, and excrete glucose from urine.Diabetes mellitus is divided into types 1 and 2, and type 1 diabetes was previously called 'juvenile diabetes', and it is a disease caused by the inability to produce any insulin. Type 2 diabetes, which is relatively deficient in insulin, is characterized by insulin resistance.Insulin treatment is required for type 1 diabetes, but type 2 diabetes is based on lifestyle correction and may require additional drug administration. In addition, many patients or people concerned about diabetes use dietary supplements to control their blood sugar, but because of the side effects of prescription drugs and the lack of definitive clinical trials of dietary supplements, it is important to choose wisely between prescription drugs and dietary supplements with the advice of a physician or expert to treat or prevent diabetes.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1374
Akash Varsadiya, Rajeshkumar Sharma, D. Kanani
In Ayurveda, Acharya Sushrut mentioned miraculous treatment for urethral stricture or mentioned as Mutrakruccha in Ayurvedic classical texts.Which briefly means difficulty in micturition. Mutrakruccha can be correlated withUrethral stricture due to the similarity between the symptoms. Many surgical and non-surgical treatments are available in modern medical science. Still, dueto thehigh recurrence and huge financial burden on the health system, Ayurvedic treatment Uttarbasti is showing promising results in the management of Urethral Stricture.Uttarbasti is the delivery of therapeutic oil or decoction via the urethra or vaginal channel.Urethral strictures can result from inflammatory, ischemic, or traumatic processes. These processes lead to scar tissue formation; scar tissue contracts and reduces the caliber of the urethral lumen, causing resistance to the flow of urine. Urethral strictures arise from various causes and can result in a range of manifestations, from an asymptomatic presentation to severe discomfort secondary to urinary retention. Retrograde urethrogram (RUG) is the main diagnostic tool to find urethral stricture and help find the length of the stricture. There is no modernmedical-science treatment for urethral stricture disease, however, urinary tract infections (UTIs) should be adequately treated before surgical intervention. Surgical treatment of urethral stricture disease is indicated when the patient has severe voiding symptoms, bladder calculi, increased postvoid residual, or urinary tract infection or when conservative management fails. Due to the high recurrence rate of surgical intervention in Urethral stricture non-invasive treatment such as Uttarbasti is always appreciated.
{"title":"Shwadamstradi Ghrita Uttarbasti the Ayurvedic Treatment of Urethral Stricture","authors":"Akash Varsadiya, Rajeshkumar Sharma, D. Kanani","doi":"10.22270/ajprd.v12i2.1374","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1374","url":null,"abstract":"In Ayurveda, Acharya Sushrut mentioned miraculous treatment for urethral stricture or mentioned as Mutrakruccha in Ayurvedic classical texts.Which briefly means difficulty in micturition. Mutrakruccha can be correlated withUrethral stricture due to the similarity between the symptoms. Many surgical and non-surgical treatments are available in modern medical science. Still, dueto thehigh recurrence and huge financial burden on the health system, Ayurvedic treatment Uttarbasti is showing promising results in the management of Urethral Stricture.Uttarbasti is the delivery of therapeutic oil or decoction via the urethra or vaginal channel.Urethral strictures can result from inflammatory, ischemic, or traumatic processes. These processes lead to scar tissue formation; scar tissue contracts and reduces the caliber of the urethral lumen, causing resistance to the flow of urine. Urethral strictures arise from various causes and can result in a range of manifestations, from an asymptomatic presentation to severe discomfort secondary to urinary retention. Retrograde urethrogram (RUG) is the main diagnostic tool to find urethral stricture and help find the length of the stricture. There is no modernmedical-science treatment for urethral stricture disease, however, urinary tract infections (UTIs) should be adequately treated before surgical intervention. Surgical treatment of urethral stricture disease is indicated when the patient has severe voiding symptoms, bladder calculi, increased postvoid residual, or urinary tract infection or when conservative management fails. Due to the high recurrence rate of surgical intervention in Urethral stricture non-invasive treatment such as Uttarbasti is always appreciated.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140701638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This comprehensive review investigates the market landscape of antihypertensive medications, undertaking a detailed comparative analysis of branded and generic options. In the face of rising global prevalence of hypertension, the study aims to provide a holistic perspective on the efficacy, safety, and market dynamics shaping the use of branded and generic drugs in the management of these chronic conditions. Utilizing data derived from market trends, sales analytics, and consumer preferences, the review scrutinizes the market behaviors and forces influencing the adoption of branded and generic antihypertensive drugs. Factors such as cost-effectiveness, patient adherence, and healthcare provider preferences are explored to shed light on the complexities associated with medication selection in the context of chronic disease management. Through an in-depth examination of industry strategies, regulatory frameworks, and the role of healthcare policies, the review aims to uncover the interplay between market dynamics and clinical considerations. It seeks to inform healthcare professionals, policymakers, and industry stakeholders about the evolving landscape of choices in antihypertensive therapies, fostering a nuanced understanding that can guide optimal decision-making in patient care and resource allocation.
{"title":"A Review: A Comparative Study of Branded and Generic Anti- Diabetic Drugs","authors":"Anuksh Telrandhe, Ketki Phadnis, Nilakshi Dhoble, Nitin Padole, Jagdish Baheti","doi":"10.22270/ajprd.v12i2.1340","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1340","url":null,"abstract":"This comprehensive review investigates the market landscape of antihypertensive medications, undertaking a detailed comparative analysis of branded and generic options. In the face of rising global prevalence of hypertension, the study aims to provide a holistic perspective on the efficacy, safety, and market dynamics shaping the use of branded and generic drugs in the management of these chronic conditions.\u0000Utilizing data derived from market trends, sales analytics, and consumer preferences, the review scrutinizes the market behaviors and forces influencing the adoption of branded and generic antihypertensive drugs. Factors such as cost-effectiveness, patient adherence, and healthcare provider preferences are explored to shed light on the complexities associated with medication selection in the context of chronic disease management.\u0000Through an in-depth examination of industry strategies, regulatory frameworks, and the role of healthcare policies, the review aims to uncover the interplay between market dynamics and clinical considerations. It seeks to inform healthcare professionals, policymakers, and industry stakeholders about the evolving landscape of choices in antihypertensive therapies, fostering a nuanced understanding that can guide optimal decision-making in patient care and resource allocation.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140700394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1375
Dr. Neelkumar B. Patel, Dr. Rajesh Kumar Sharma, Dr. Hardik Desai
Over time, an inguinal hernia may develop due to increased pressure on the walls of the abdominal muscles from activities such as straining, prolonged coughing, being overweight, or lifting heavy weights. Acharya Sushruta referred to inguinal hernia as Antravridhhi[1]. This condition may be associated with symptoms such as dragging pain and discomfort. Paresthesia may occur in some patients due to compression or irritation of the inguinal nerves by the hernia. An indirect inguinal hernia which does not extend to the scrotal sac should be managed as vata vridhhi[2]. In describing the operative management of vata vridhhi, Acharya Sushruta recommended certain therapeutic procedures as a purvakarma of Vatavridhhi chikitsa. The patient undergo Nityavirechana karma with Eranda taila and Milk for 7 days, followed by hernioplasty on the 8th day. Tension-free mesh hernia repair has become the predominant method for treating inguinal hernias.
{"title":"An Indirect Inguinal Hernia Repair after Nitya Virechana a Case Report","authors":"Dr. Neelkumar B. Patel, Dr. Rajesh Kumar Sharma, Dr. Hardik Desai","doi":"10.22270/ajprd.v12i2.1375","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1375","url":null,"abstract":"Over time, an inguinal hernia may develop due to increased pressure on the walls of the abdominal muscles from activities such as straining, prolonged coughing, being overweight, or lifting heavy weights. Acharya Sushruta referred to inguinal hernia as Antravridhhi[1]. This condition may be associated with symptoms such as dragging pain and discomfort. Paresthesia may occur in some patients due to compression or irritation of the inguinal nerves by the hernia. An indirect inguinal hernia which does not extend to the scrotal sac should be managed as vata vridhhi[2]. In describing the operative management of vata vridhhi, Acharya Sushruta recommended certain therapeutic procedures as a purvakarma of Vatavridhhi chikitsa. The patient undergo Nityavirechana karma with Eranda taila and Milk for 7 days, followed by hernioplasty on the 8th day. Tension-free mesh hernia repair has become the predominant method for treating inguinal hernias.\u0000 \u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.22270/ajprd.v12i2.1367
Hemlata Sharma, K. Gulati, A. Ray
Bronchial asthma is a chronic inflammatory respiratory disease characterized by bronchoconstriction and hyperresponsiveness of the bronchial airways. The treatment for bronchial asthma is mainly aimed at relieving symptoms by bronchodilators and controlling asthmatic attacks with anti-inflammatory agents. These therapeutic strategies are associated with several adverse drug effects and high cost that may negatively affect the compliance to therapy. Chronic asthma also results in structural remodeling of the airways which enhances the incidence of refractory asthma and increases morbidity/mortality. It is therefore important to explore adjuncts from alternative forms of therapy to compliment/supplement the conventional treatment. The study assessed the effects of Aerva Lanata Linn., a medicinal plant used in the traditional systems of medicine, on airway remodeling in an experimental model of asthma in rats. Wistar rats were immunized on day 0 with ovalbumin and Al(OH)3 and challenged with aerosolized ovalbumin from day 15 to 22. The rats were treated orally with various doses of standardized aqueous extract of whole plant of Aerva Lanata Linn. or prednisolone (10 mg/kg) for 22 days. After 24 hrs of last challenge, blood, bronchoalveolar lavage (BAL) fluid and lung tissue were collected and assayed for markers of structural remodeling viz, (a) cytokine levels (TGF-β and IL-13); (b) hydroxyproline content, and (c) histopathology. The results showed that Aerva Lanata Linn. markedly reduced the levels of TGF-β, IL-13 in both blood and BAL fluid and hydroxyproline content in lung homogenates. Histopathological examination of lung tissue confirmed the modulatory effects of Aerva Lanata Linn. on airway remodeling as evidenced by reductions in goblet cell hyperplasia, inflammatory cells infiltration and sub epithelial fibrosis, as compared to that in the experimental (disease control) group. The results showed that Aerva Lanata Linn. Attenuated the histopathological changes and biochemical markers of airway remodeling by altering the levels of IL-13 and TGFβ, and the study suggested that it could be beneficial in cases of chronic bronchial asthma.
{"title":"Cellular and molecular mechanisms involved in the protective effects of Aerva Lanata Linn.on airways remodeling in experimental model of bronchial asthma in rats","authors":"Hemlata Sharma, K. Gulati, A. Ray","doi":"10.22270/ajprd.v12i2.1367","DOIUrl":"https://doi.org/10.22270/ajprd.v12i2.1367","url":null,"abstract":"Bronchial asthma is a chronic inflammatory respiratory disease characterized by bronchoconstriction and hyperresponsiveness of the bronchial airways. The treatment for bronchial asthma is mainly aimed at relieving symptoms by bronchodilators and controlling asthmatic attacks with anti-inflammatory agents. These therapeutic strategies are associated with several adverse drug effects and high cost that may negatively affect the compliance to therapy. Chronic asthma also results in structural remodeling of the airways which enhances the incidence of refractory asthma and increases morbidity/mortality. It is therefore important to explore adjuncts from alternative forms of therapy to compliment/supplement the conventional treatment. The study assessed the effects of Aerva Lanata Linn., a medicinal plant used in the traditional systems of medicine, on airway remodeling in an experimental model of asthma in rats. Wistar rats were immunized on day 0 with ovalbumin and Al(OH)3 and challenged with aerosolized ovalbumin from day 15 to 22. The rats were treated orally with various doses of standardized aqueous extract of whole plant of Aerva Lanata Linn. or prednisolone (10 mg/kg) for 22 days. After 24 hrs of last challenge, blood, bronchoalveolar lavage (BAL) fluid and lung tissue were collected and assayed for markers of structural remodeling viz, (a) cytokine levels (TGF-β and IL-13); (b) hydroxyproline content, and (c) histopathology. The results showed that Aerva Lanata Linn. markedly reduced the levels of TGF-β, IL-13 in both blood and BAL fluid and hydroxyproline content in lung homogenates. Histopathological examination of lung tissue confirmed the modulatory effects of Aerva Lanata Linn. on airway remodeling as evidenced by reductions in goblet cell hyperplasia, inflammatory cells infiltration and sub epithelial fibrosis, as compared to that in the experimental (disease control) group. The results showed that Aerva Lanata Linn. Attenuated the histopathological changes and biochemical markers of airway remodeling by altering the levels of IL-13 and TGFβ, and the study suggested that it could be beneficial in cases of chronic bronchial asthma.\u0000 ","PeriodicalId":8526,"journal":{"name":"Asian Journal of Pharmaceutical Research and Development","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140701884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：